Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

The Ligands for Human IgG and Their Effector Functions.

de Taeye SW, Rispens T, Vidarsson G.

Antibodies (Basel). 2019 Apr 25;8(2). pii: E30. doi: 10.3390/antib8020030. Review.

2.

Functional diversification of hybridoma-produced antibodies by CRISPR/HDR genomic engineering.

van der Schoot JMS, Fennemann FL, Valente M, Dolen Y, Hagemans IM, Becker AMD, Le Gall CM, van Dalen D, Cevirgel A, van Bruggen JAC, Engelfriet M, Caval T, Bentlage AEH, Fransen MF, Nederend M, Leusen JHW, Heck AJR, Vidarsson G, Figdor CG, Verdoes M, Scheeren FA.

Sci Adv. 2019 Aug 28;5(8):eaaw1822. doi: 10.1126/sciadv.aaw1822. eCollection 2019 Aug.

3.

Anti-glycoprotein Ibα autoantibodies do not impair circulating thrombopoietin levels in immune thrombocytopenia patients.

Porcelijn L, Schmidt DE, van der Schoot CE, Vidarsson G, de Haas M, Kapur R.

Haematologica. 2019 Jul 11. pii: haematol.2019.228908. doi: 10.3324/haematol.2019.228908. [Epub ahead of print]

4.

Human DC-SIGN and CD23 do not interact with human IgG.

Temming AR, Dekkers G, van de Bovenkamp FS, Plomp HR, Bentlage AEH, Szittner Z, Derksen NIL, Wuhrer M, Rispens T, Vidarsson G.

Sci Rep. 2019 Jul 10;9(1):9995. doi: 10.1038/s41598-019-46484-2.

5.

Glycoform-resolved FcɣRIIIa affinity chromatography-mass spectrometry.

Lippold S, Nicolardi S, Domínguez-Vega E, Heidenreich AK, Vidarsson G, Reusch D, Haberger M, Wuhrer M, Falck D.

MAbs. 2019 Oct;11(7):1191-1196. doi: 10.1080/19420862.2019.1636602. Epub 2019 Aug 2.

6.

Transient and chronic childhood immune thrombocytopenia are distinctly affected by Fc-γ receptor polymorphisms.

Schmidt DE, Heitink-Pollé KMJ, Laarhoven AG, Bruin MCA, Veldhuisen B, Nagelkerke SQ, Kuijpers TW, Porcelijn L, van der Schoot CE, Vidarsson G, de Haas M.

Blood Adv. 2019 Jul 9;3(13):2003-2012. doi: 10.1182/bloodadvances.2019000068.

7.

Reduced FcRn-mediated transcytosis of IgG2 due to a missing Glycine in its lower hinge.

Stapleton NM, Brinkhaus M, Armour KL, Bentlage AEH, de Taeye SW, Temming AR, Mok JY, Brasser G, Maas M, van Esch WJE, Clark MR, Williamson LM, van der Schoot CE, Vidarsson G.

Sci Rep. 2019 May 14;9(1):7363. doi: 10.1038/s41598-019-40731-2.

8.

Biased N-Glycosylation Site Distribution and Acquisition across the Antibody V Region during B Cell Maturation.

Koers J, Derksen NIL, Ooijevaar-de Heer P, Nota B, van de Bovenkamp FS, Vidarsson G, Rispens T.

J Immunol. 2019 Apr 15;202(8):2220-2228. doi: 10.4049/jimmunol.1801622. Epub 2019 Mar 8.

PMID:
30850477
9.

FcγRIIIb Restricts Antibody-Dependent Destruction of Cancer Cells by Human Neutrophils.

Treffers LW, van Houdt M, Bruggeman CW, Heineke MH, Zhao XW, van der Heijden J, Nagelkerke SQ, Verkuijlen PJJH, Geissler J, Lissenberg-Thunnissen S, Valerius T, Peipp M, Franke K, van Bruggen R, Kuijpers TW, van Egmond M, Vidarsson G, Matlung HL, van den Berg TK.

Front Immunol. 2019 Jan 30;9:3124. doi: 10.3389/fimmu.2018.03124. eCollection 2018.

10.

Development of a recombinant anti-Vel immunoglobulin M to identify Vel-negative donors.

van der Rijst MVE, Lissenberg-Thunnissen SN, Ligthart PC, Visser R, Jongerius JM, Voorn L, Veldhuisen B, Vidarsson G, van den Akker E, van der Schoot CE.

Transfusion. 2019 Apr;59(4):1359-1366. doi: 10.1111/trf.15147. Epub 2019 Jan 31.

PMID:
30702752
11.

An unusual presentation of a patient with severe hypogammaglobulinemia.

Hoffman TW, van Kessel DA, van Tol MJD, Vidarsson G, Jol-van der Zijde EC, Rijkers GT, van Velzen-Blad H.

Clin Case Rep. 2018 Oct 26;6(12):2416-2423. doi: 10.1002/ccr3.1877. eCollection 2018 Dec.

12.

Multiplex blood group typing by cellular surface plasmon resonance imaging.

Szittner Z, Bentlage AEH, van der Donk E, Ligthart PC, Lissenberg-Thunnissen S, van der Schoot CE, Vidarsson G.

Transfusion. 2019 Feb;59(2):754-761. doi: 10.1111/trf.15071. Epub 2018 Nov 29.

PMID:
30488958
13.

IgG Glyco-Engineering to Improve IVIg Potency.

Bruggeman CW, Dekkers G, Visser R, Goes NWM, van den Berg TK, Rispens T, Vidarsson G, Kuijpers TW.

Front Immunol. 2018 Oct 23;9:2442. doi: 10.3389/fimmu.2018.02442. eCollection 2018.

14.

Trends in SPR Cytometry: Advances in Label-Free Detection of Cell Parameters.

Schasfoort RBM, Abali F, Stojanovic I, Vidarsson G, Terstappen LWMM.

Biosensors (Basel). 2018 Oct 30;8(4). pii: E102. doi: 10.3390/bios8040102. Review.

15.

A variant RhAG protein encoded by the RHAG*572A allele causes serological weak D expression while maintaining normal RhCE phenotypes.

Wen J, Verhagen OJHM, Jia S, Liang Q, Wang Z, Wei L, Luo H, Luo G, Vidarsson G, van den Akker E, Ji Y, van der Schoot CE.

Transfusion. 2019 Jan;59(1):405-411. doi: 10.1111/trf.14969. Epub 2018 Oct 4.

PMID:
30284303
16.

Anti-HLA antibodies with complementary and synergistic interaction geometries promote classical complement activation on platelets.

Rijkers M, Schmidt D, Lu N, Kramer CSM, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Leebeek FWG, Jansen AJG, Jongerius I, Zeerleder SS, Vidarsson G, Voorberg J, de Haas M.

Haematologica. 2019 Feb;104(2):403-416. doi: 10.3324/haematol.2018.201665. Epub 2018 Sep 27.

17.

FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model.

Sow HS, Benonisson H, Breukel C, Visser R, Verhagen OJHM, Bentlage AEH, Brouwers C, Claassens JWC, Linssen MM, Camps M, van Hall T, Ossendorp F, Fransen MF, Vidarsson G, Verbeek JS.

Int J Cancer. 2019 Jan 15;144(2):345-354. doi: 10.1002/ijc.31899. Epub 2018 Nov 12.

PMID:
30259976
18.

Anti-ADAMTS13 Autoantibodies against Cryptic Epitopes in Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Roose E, Vidarsson G, Kangro K, Verhagen OJHM, Mancini I, Desender L, Pareyn I, Vandeputte N, Vandenbulcke A, Vendramin C, Schelpe AS, Voorberg J, Azerad MA, Gilardin L, Scully M, Dierickx D, Deckmyn H, De Meyer SF, Peyvandi F, Vanhoorelbeke K.

Thromb Haemost. 2018 Oct;118(10):1729-1742. doi: 10.1055/s-0038-1669459. Epub 2018 Sep 20.

19.

The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris-Analysis of Four Different Ethnic Cohorts.

Recke A, Konitzer S, Lemcke S, Freitag M, Sommer NM, Abdelhady M, Amoli MM, Benoit S, El-Chennawy F, Eldarouti M, Eming R, Gläser R, Günther C, Hadaschik E, Homey B, Lieb W, Peitsch WK, Pföhler C, Robati RM, Saeedi M, Sárdy M, Sticherling M, Uzun S, Worm M, Zillikens D, Ibrahim S, Vidarsson G, Schmidt E; German AIBD Genetic Study Group.

Front Immunol. 2018 Aug 2;9:1788. doi: 10.3389/fimmu.2018.01788. eCollection 2018.

20.

Mechanisms of inside-out signaling of the high-affinity IgG receptor FcγRI.

Brandsma AM, Schwartz SL, Wester MJ, Valley CC, Blezer GLA, Vidarsson G, Lidke KA, Ten Broeke T, Lidke DS, Leusen JHW.

Sci Signal. 2018 Jul 24;11(540). pii: eaaq0891. doi: 10.1126/scisignal.aaq0891.

PMID:
30042128
21.

Intravenous immunoglobulin vs observation in childhood immune thrombocytopenia: a randomized controlled trial.

Heitink-Pollé KMJ, Uiterwaal CSPM, Porcelijn L, Tamminga RYJ, Smiers FJ, van Woerden NL, Wesseling J, Vidarsson G, Laarhoven AG, de Haas M, Bruin MCA; TIKI Investigators.

Blood. 2018 Aug 30;132(9):883-891. doi: 10.1182/blood-2018-02-830844. Epub 2018 Jun 26.

PMID:
29945954
22.

Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.

van Schie KA, Kruithof S, Ooijevaar-de Heer P, Derksen NIL, van de Bovenkamp FS, Saris A, Vidarsson G, Bentlage AEH, Jiskoot W, Romeijn S, Koning RI, Bos E, Stork EM, Koeleman CAM, Wuhrer M, Wolbink G, Rispens T.

Ann Rheum Dis. 2018 Oct;77(10):1471-1479. doi: 10.1136/annrheumdis-2018-213299. Epub 2018 Jun 26.

PMID:
29945923
23.

A subset of anti-HLA antibodies induces FcγRIIa-dependent platelet activation.

Rijkers M, Saris A, Heidt S, Mulder A, Porcelijn L, Claas FHJ, Bierings R, Leebeek FWG, Jansen AJG, Vidarsson G, Voorberg J, de Haas M.

Haematologica. 2018 Oct;103(10):1741-1752. doi: 10.3324/haematol.2018.189365. Epub 2018 Jun 1.

24.

Emerging Concepts in Immune Thrombocytopenia.

Swinkels M, Rijkers M, Voorberg J, Vidarsson G, Leebeek FWG, Jansen AJG.

Front Immunol. 2018 Apr 30;9:880. doi: 10.3389/fimmu.2018.00880. eCollection 2018. Review.

25.

Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.

Crooks ET, Grimley SL, Cully M, Osawa K, Dekkers G, Saunders K, Rämisch S, Menis S, Schief WR, Doria-Rose N, Haynes B, Murrell B, Cale EM, Pegu A, Mascola JR, Vidarsson G, Binley JM.

PLoS Pathog. 2018 May 2;14(5):e1007024. doi: 10.1371/journal.ppat.1007024. eCollection 2018 May.

26.

Dimeric IgG complexes from IVIg are incapable of inducing in vitro neutrophil degranulation or complement activation.

Kustiawan I, Derksen NIL, Guhr T, Kruithof S, Jiskoot W, Vidarsson G, Rispens T.

PLoS One. 2018 Apr 10;13(4):e0195729. doi: 10.1371/journal.pone.0195729. eCollection 2018.

27.

Novel Concepts of Altered Immunoglobulin G Galactosylation in Autoimmune Diseases.

Dekkers G, Rispens T, Vidarsson G.

Front Immunol. 2018 Mar 19;9:553. doi: 10.3389/fimmu.2018.00553. eCollection 2018. Review.

28.

Whole-Genome Expression Profiling in Skin Reveals SYK As a Key Regulator of Inflammation in Experimental Epidermolysis Bullosa Acquisita.

Samavedam UK, Mitschker N, Kasprick A, Bieber K, Schmidt E, Laskay T, Recke A, Goletz S, Vidarsson G, Schulze FS, Armbrust M, Schulze Dieckhoff K, Pas HH, Jonkman MF, Kalies K, Zillikens D, Gupta Y, Ibrahim SM, Ludwig RJ.

Front Immunol. 2018 Feb 15;9:249. doi: 10.3389/fimmu.2018.00249. eCollection 2018.

29.

FcαRI co-stimulation converts human intestinal CD103+ dendritic cells into pro-inflammatory cells through glycolytic reprogramming.

Hansen IS, Krabbendam L, Bernink JH, Loayza-Puch F, Hoepel W, van Burgsteden JA, Kuijper EC, Buskens CJ, Bemelman WA, Zaat SAJ, Agami R, Vidarsson G, van den Brink GR, de Jong EC, Wildenberg ME, Baeten DLP, Everts B, den Dunnen J.

Nat Commun. 2018 Feb 28;9(1):863. doi: 10.1038/s41467-018-03318-5.

30.

Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.

Falkenburg WJJ, Kempers AC, Dekkers G, Ooijevaar-de Heer P, Bentlage AEH, Vidarsson G, van Schaardenburg D, Toes REM, Scherer HU, Rispens T.

Rheumatology (Oxford). 2018 Apr 1;57(4):771. doi: 10.1093/rheumatology/key056. No abstract available.

PMID:
29481646
31.

Fc-Glycosylation in Human IgG1 and IgG3 Is Similar for Both Total and Anti-Red-Blood Cell Anti-K Antibodies.

Sonneveld ME, Koeleman CAM, Plomp HR, Wuhrer M, van der Schoot CE, Vidarsson G.

Front Immunol. 2018 Jan 31;9:129. doi: 10.3389/fimmu.2018.00129. eCollection 2018.

32.

Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region.

van de Bovenkamp FS, Derksen NIL, Ooijevaar-de Heer P, van Schie KA, Kruithof S, Berkowska MA, van der Schoot CE, IJspeert H, van der Burg M, Gils A, Hafkenscheid L, Toes REM, Rombouts Y, Plomp R, Wuhrer M, van Ham SM, Vidarsson G, Rispens T.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):1901-1906. doi: 10.1073/pnas.1711720115. Epub 2018 Feb 5.

33.

Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.

Stapleton NM, Armstrong-Fisher SS, Andersen JT, van der Schoot CE, Porter C, Page KR, Falconer D, de Haas M, Williamson LM, Clark MR, Vidarsson G, Armour KL.

Mol Immunol. 2018 Mar;95:1-9. doi: 10.1016/j.molimm.2018.01.006. Epub 2018 Feb 20.

34.

Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice.

Dekkers G, Bentlage AEH, Plomp R, Visser R, Koeleman CAM, Beentjes A, Mok JY, van Esch WJE, Wuhrer M, Rispens T, Vidarsson G.

Mol Immunol. 2018 Feb;94:54-60. doi: 10.1016/j.molimm.2017.12.006. Epub 2017 Dec 19.

35.

Rheumatoid factors do not preferentially bind to ACPA-IgG or IgG with altered galactosylation.

Falkenburg WJJ, Kempers AC, Dekkers G, Ooijevaar-de Heer P, Bentlage AEH, Vidarsson G, van Schaardenburg D, Toes REM, Scherer HU, Rispens T.

Rheumatology (Oxford). 2017 Nov 1;56(11):2025-2030. doi: 10.1093/rheumatology/kex284. Erratum in: Rheumatology (Oxford). 2018 Apr 1;57(4):771.

PMID:
28977504
36.

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities.

Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, Lissenberg-Thunnissen SN, Visser R, Brouwer M, Mok JY, Matlung H, van den Berg TK, van Esch WJE, Kuijpers TW, Wouters D, Rispens T, Wuhrer M, Vidarsson G.

Front Immunol. 2017 Aug 2;8:877. doi: 10.3389/fimmu.2017.00877. eCollection 2017.

37.

Patients with IgG1-anti-red blood cell autoantibodies show aberrant Fc-glycosylation.

Sonneveld ME, de Haas M, Koeleman C, de Haan N, Zeerleder SS, Ligthart PC, Wuhrer M, van der Schoot CE, Vidarsson G.

Sci Rep. 2017 Aug 15;7(1):8187. doi: 10.1038/s41598-017-08654-y.

38.

Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.

Bloemendaal FM, Levin AD, Wildenberg ME, Koelink PJ, McRae BL, Salfeld J, Lum J, van der Neut Kolfschoten M, Claassens JW, Visser R, Bentlage A, D'Haens GRAM, Verbeek JS, Vidarsson G, van den Brink GR.

Gastroenterology. 2017 Nov;153(5):1351-1362.e4. doi: 10.1053/j.gastro.2017.07.021. Epub 2017 Jul 27.

PMID:
28756234
39.

DARC extracellular domain remodeling in maturating reticulocytes explains Plasmodium vivax tropism.

Ovchynnikova E, Aglialoro F, Bentlage AEH, Vidarsson G, Salinas ND, von Lindern M, Tolia NH, van den Akker E.

Blood. 2017 Sep 21;130(12):1441-1444. doi: 10.1182/blood-2017-03-774364. Epub 2017 Jul 28.

40.

Identification of sequence variants influencing immunoglobulin levels.

Jonsson S, Sveinbjornsson G, de Lapuente Portilla AL, Swaminathan B, Plomp R, Dekkers G, Ajore R, Ali M, Bentlage AEH, Elmér E, Eyjolfsson GI, Gudjonsson SA, Gullberg U, Gylfason A, Halldorsson BV, Hansson M, Holm H, Johansson Å, Johnsson E, Jonasdottir A, Ludviksson BR, Oddsson A, Olafsson I, Olafsson S, Sigurdardottir O, Sigurdsson A, Stefansdottir L, Masson G, Sulem P, Wuhrer M, Wihlborg AK, Thorleifsson G, Gudbjartsson DF, Thorsteinsdottir U, Vidarsson G, Jonsdottir I, Nilsson B, Stefansson K.

Nat Genet. 2017 Aug;49(8):1182-1191. doi: 10.1038/ng.3897. Epub 2017 Jun 19.

PMID:
28628107
41.

Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile.

Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, Koeleman CAM, Wuhrer M, van den Berg TK, Rispens T, Vidarsson G, Kuijpers TW.

J Immunol. 2017 Jul 1;199(1):204-211. doi: 10.4049/jimmunol.1700116. Epub 2017 May 31.

42.

Human IgG3 with extended half-life does not improve Fc-gamma receptor-mediated cancer antibody therapies in mice.

Braster R, Grewal S, Visser R, Einarsdottir HK, van Egmond M, Vidarsson G, Bögels M.

PLoS One. 2017 May 19;12(5):e0177736. doi: 10.1371/journal.pone.0177736. eCollection 2017.

43.

Affinity of human IgG subclasses to mouse Fc gamma receptors.

Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G.

MAbs. 2017 Jul;9(5):767-773. doi: 10.1080/19420862.2017.1323159. Epub 2017 May 2.

44.

Fcγ receptor expression on splenic macrophages in adult immune thrombocytopenia.

Audia S, Santegoets K, Laarhoven AG, Vidarsson G, Facy O, Ortega-Deballon P, Samson M, Janikashvili N, Saas P, Bonnotte B, Radstake TR.

Clin Exp Immunol. 2017 May;188(2):275-282. doi: 10.1111/cei.12935. Epub 2017 Feb 28.

45.

RhIg-prophylaxis is not influenced by FCGR2/3 polymorphisms involved in red blood cell clearance.

Stegmann TC, Veldhuisen B, Nagelkerke SQ, Winkelhorst D, Schonewille H, Verduin EP, Kuijpers TW, de Haas M, Vidarsson G, van der Schoot CE.

Blood. 2017 Feb 23;129(8):1045-1048. doi: 10.1182/blood-2016-05-716365. Epub 2017 Jan 12. No abstract available.

PMID:
28082442
46.

Antigen specificity determines anti-red blood cell IgG-Fc alloantibody glycosylation and thereby severity of haemolytic disease of the fetus and newborn.

Sonneveld ME, Koelewijn J, de Haas M, Admiraal J, Plomp R, Koeleman CA, Hipgrave Ederveen AL, Ligthart P, Wuhrer M, van der Schoot CE, Vidarsson G.

Br J Haematol. 2017 Feb;176(4):651-660. doi: 10.1111/bjh.14438. Epub 2016 Nov 28.

PMID:
27891581
47.

Multi-level glyco-engineering techniques to generate IgG with defined Fc-glycans.

Dekkers G, Plomp R, Koeleman CA, Visser R, von Horsten HH, Sandig V, Rispens T, Wuhrer M, Vidarsson G.

Sci Rep. 2016 Nov 22;6:36964. doi: 10.1038/srep36964.

48.

Anti-Hinge Antibodies Recognize IgG Subclass- and Protease-Restricted Neoepitopes.

Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, Tsang-A-Sjoe MW, Bultink IE, Voskuyl AE, Bentlage AE, Vidarsson G, Wolbink G, Rispens T.

J Immunol. 2017 Jan 1;198(1):82-93. Epub 2016 Nov 18.

49.

PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.

Koga H, Recke A, Vidarsson G, Pas HH, Jonkman MF, Hashimoto T, Kasprick A, Ghorbanalipoor S, Tenor H, Zillikens D, Ludwig RJ.

J Invest Dermatol. 2016 Nov;136(11):2211-2220. doi: 10.1016/j.jid.2016.06.619. Epub 2016 Jul 5.

50.

MALDI-TOF-MS reveals differential N-linked plasma- and IgG-glycosylation profiles between mothers and their newborns.

Jansen BC, Bondt A, Reiding KR, Scherjon SA, Vidarsson G, Wuhrer M.

Sci Rep. 2016 Sep 26;6:34001. doi: 10.1038/srep34001.

Supplemental Content

Loading ...
Support Center